argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

By /

argenx SE announced its plan to advance to a second dose cohort with the Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy.

Scroll to Top